Who makes Remifentanil [Ultiva]?

Remifentanil [Ultiva] is developed by Medical University of Warsaw.

What development phase is Remifentanil [Ultiva] in?

Remifentanil [Ultiva] is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Remifentanil [Ultiva]

Medical University of Warsaw · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Remifentanil [Ultiva]
Also known as	remifentanil hydrochloride for injection
Sponsor	Medical University of Warsaw
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Remifentanil [Ultiva] CI brief — competitive landscape report
Remifentanil [Ultiva] updates RSS · CI watch RSS
Medical University of Warsaw portfolio CI